Evidence map›Paper›PMID 27151743›Full record

ReviewJournal of internal medicine2016

Amyloid formation: functional friend or fearful foe?

P Bergman, N R Roan, U Römling, C L Bevins, J Münch

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Supramolecular Bait to Trigger Non-Equilibrium Co-Assembly and Clearance of Aβ42.Angewandte Chemie (International ed. in English) · 2021
    Article
  7. Review
  8. Review
  9. Article
  10. IL-1β PromotesFrontiers in immunology · 2019
    Article
  11. Article
  12. Article
  13. Amyloid assembly and disassembly.Journal of cell science · 2018
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

P BergmanDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
N R RoanDepartment of Urology, University of California, San Francisco, CA, USA.
U RömlingDepartment of Microbiology, Tumor and Cellbiology, Karolinska Institutet, Stockholm, Sweden.
C L BevinsDepartment of Microbiology and Immunology, School of Medicine, University of California, Davis, CA, USA.
J MünchInstitute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
Karolinska Institutet · SEUniversity Hospital Ulm · DEUniversity of California, Davis · USUniversity of California, San Francisco · US

Funding

Novel Defensins in Human Epithelial TissuesR37AI032738 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BEVINS, CHARLES L · 2015 to 2022
$3.1M
Novel Defensins of Human EpitheliaR01AI032738 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BEVINS, CHARLES L · 1993 to 2009
$2.3M
In vivo Models of Defensin ActivityR01AI050843 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BEVINS, CHARLES L · 2002 to 2006
$1.6M
Exploring the Role of Semen Amyloids in Promoting HIV Infection and FertilizationR00AI104262 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2015 to 2016
$493k
Characterization of Gallic Acid as a Novel HIV Microbicide CandidateR21AI116252 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2015 to 2016
$436k
New Mouse Models of Paneth Cell Defensin FunctionR21AI099519 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BEVINS, CHARLES L · 2012 to 2013
$423k
NIAID NIH HHS R00 AI104262NIAID NIH HHS R01 AI032738NIAID NIH HHS R01 AI050843NIAID NIH HHS R21 AI099519NIAID NIH HHS R21 AI116252NIAID NIH HHS R37 AI032738
6 · The paper itself

Abstract

Amyloid formation has been most studied in the context of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as in amyloidosis. However, it is becoming increasingly clear that amyloid is also present in the healthy setting; for example nontoxic amyloid formation is important for melanin synthesis and in innate immunity. Furthermore, bacteria have mechanisms to produce functional amyloid structures with important roles in bacterial physiology and interaction with host cells. Here, we will discuss some novel aspects of fibril-forming proteins in humans and bacteria. First, the amyloid-forming properties of the antimicrobial peptide human defensin 6 (HD6) will be considered. Intriguingly, unlike other antimicrobial peptides, HD6 does not kill bacteria. However, recent data show that HD6 can form amyloid structures at the gut mucosa with strong affinity for bacterial surfaces. These so-called nanonets block bacterial invasion by entangling the bacteria in net-like structures. Next, the role of functional amyloid fibrils in human semen will be discussed. These fibrils were discovered through their property to enhance HIV infection but they may also have other yet unknown functions. Finally, the role of amyloid formation in bacteria will be reviewed. The recent finding that bacteria can make amyloid in a controlled fashion without toxic effects is of particular interest and may have implications for human disease. The role of amyloid in health and disease is beginning to be unravelled, and here, we will review some of the most recent findings in this exciting area.

Indexed as

alpha-DefensinsAmyloidBacteriaBacterial InfectionsBacterial Physiological PhenomenaHIV InfectionsHumansImmunity, InnateIntestinal MucosaMicrobiotaProtein FoldingSemenalpha-DefensinsAmyloidDEFA6 protein, humanamyloiddefensinHIVnetsPanethsemen

Identifiers

PMID27151743
PMCPMC4956559
OpenAlexW2347071512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.